Fortress Biotech, Inc. - 9.375%
FBIOP
Positions held
Your positionsFBIOP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | $491.67M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 3.61 | Beta | 1.25 | Dividend yield | 0.00% |
| Revenue growth | 14.0% | Earnings growth | — | Gross margin | 63.3% | Operating margin | -53.5% |
| Profit margin | 1.6% | ROE | 116.0% | ROA | -7.8% | Debt / equity | 0.26 |
| Current ratio | 3.96 | Free cash flow | -$17.14M | Analyst recommendation | none | Mean target | — |
| 52w high | $21.43 | 52w low | $6.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $18.7M | $16.0M | $16.1M | $17.6M | $16.4M | — |
| Op margin | -53.5% | -48.3% | -29.8% | -38.6% | -222.2% | — |
| Net income | -$0.5M | $110M | -$3.9M | $5.8M | $15.5M | — |
| Gross margin | 67.2% | 61.2% | 66.2% | 67.4% | 69.9% | — |
| Gross profit | $12.6M | $9.8M | $10.6M | $11.9M | $11.5M | — |
| Operating income | -$10.0M | -$7.7M | -$4.8M | -$6.8M | -$36.5M | — |
- Revenue +17% vs prior quarter ($19M vs $16M).
- Gross margin 67.2% (was 61.2% prior quarter).
- Operating margin compressed to -53.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | — |
| Op margin | -111.0% | -192.9% | -164.7% | -268.8% | — |
| Net income | $6.8M | -$46.0M | -$60.6M | -$86.6M | — |
| Gross margin | 66.9% | 63.8% | 72.9% | 59.4% | — |
| Gross profit | $42.3M | $36.8M | $61.6M | $45.0M | — |
| Operating income | -$70.2M | -$111M | -$139M | -$204M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-14 · Fortress Biotech, Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-12 · Fortress Biotech Q2 Earnings Call Highlights
2026-08-12 · Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-05 · Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
2026-07-27 · Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Price (daily)
Full chart · RSI · MACD · patterns